4-羟基-2-吗啉嘧啶-5-羧酸乙酯 | 25693-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-羟基-2-吗啉嘧啶-5-羧酸乙酯
• 中文别名: 乙基-4-羟基-2-吗啉基嘧啶-5-甲酸叔丁酯
• 英文名称: 4-Hydroxy-2-morpholino-pyrimidin-5-carbonsaeure-ethylester
• 英文别名: 2-morpholin-4-yl-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester；4-hydroxy-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester；5-carbethoxy-4-hydroxy-2-morpholino-pyrimidine；ethyl 4-hydroxy-2-morpholinopyrimidine-5-carboxylate；ethyl 4-hydroxy-2-morpholin-4-ylpyrimidine-5-carboxylate
• CAS: 25693-41-8
• 化学式: C₁₁H₁₅N₃O₄
• mdl: MFCD15481328
• 分子量: 253.258
• InChiKey: JUWSURXCRLIMJE-UHFFFAOYSA-N

物化性质

• 熔点：
  168-170 °C(Solv: ethanol (64-17-5))
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-hydroxy-2-morpholinopyrimidine-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-hydroxy-2-morpholinopyrimidine-5-carboxylate
CAS number: 25693-41-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15N3O4
Molecular weight: 253.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羟基-2-吗啉嘧啶-5-羧酸乙酯 在 五氯化磷 、 三氯氧磷 作用下， 反应 3.0h， 以68%的产率得到4-氯-2-吗啉嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-one新衍生物的微波辅助合成及抗菌评价

  摘要：

  摘要 在经典加热下以 4-羟基-2-甲硫基-嘧啶-5-羧酸乙酯 (1) 为起始原料合成新的 1,2-二氢-3H-吡唑并[3,4-d] 嘧啶-3-酮 4-6并报告了微波诱导条件。以氯霉素和链霉素为参比药物对合成化合物的抗菌活性进行了评价。

  DOI：

  10.1515/hc-2015-0145
• 作为产物：
  描述：

  2-morpholin-4-yl-4-(4-nitro-benzyloxy)-pyrimidine-5-carboxylic acid ethyl ester 在 palladium on carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 20.17h， 以95.6%的产率得到4-羟基-2-吗啉嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  [EN] PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K)
  [FR] PYRIMIDINES A TITRE D'INHIBITEURS DE PHOSPHOINOSITIDE-3-KINASES (PI3K)

  摘要：

  本发明提供了式（I）的嘧啶化合物：其中R4、R6和Y具有规范中定义的任何值，并且其药用盐，这些化合物可用作治疗疾病和病症的药物，包括炎症性疾病、心血管疾病和癌症的药物。还提供了包含一种或多种式（I）化合物的药物组合物。

  公开号：

  WO2005042519A1

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• [EN] NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DE L'AZOTE COMME INHIBITEURS DE PI3K-DELTA
  申请人：AMGEN INC

  公开号：WO2012003264A1

  公开（公告）日：2012-01-05

  Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  以下化合物的替代双环杂环芳基，用于治疗一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定膀胱疾病、牛皮癣、伴有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫性疾病，如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、Sjoegren综合征和自身免疫性溶血性贫血，包括所有形式的过敏反应，本发明还提供了治疗依赖或与p110活性相关的癌症的方法，包括但不限于介导的白血病，如急性髓系白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增生性疾病（MPD）、慢性髓系白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• 2,4,5,6-Tetrasubstituted pyrimidines and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US03975384A1

  公开（公告）日：1976-08-17

  Compounds of the formula ##SPC1## Wherein R.sub.1 is alkoxy of 1 to 3 carbon atoms, morpholino, thiomorpholino, 1-oxido-thiomorpholino, 1,1-dioxido-thiomorpholino, or ##EQU1## where A is hydrogen, alkanoyl of 1 to 4 carbon atoms, alkenoyl of 2 to 4 carbon atoms, methoxy-(alkanoyl of 1 to 4 carbon atoms), carboxyl-(alkanoyl of 1 to 4 carbon atoms), acetyl-(alkanoyl of 1 to 4 carbon atoms), methoxy-(alkenoyl of 2 to 4 carbon atoms), carboxyl-(alkenoyl of 2 to 4 carbon atoms), acetyl-(alkenoyl of 2 to 4 carbon atoms), aminocarbonyl, mono(alkyl of 1 to 4 carbon atoms)-aminocarbonyl, di-(alkyl of 1 to 4 carbon atoms)-aminocarbonyl, methoxymethylaminocarbonyl, pyridinoyl, salicyloyl, furanoyl, or (alkyl of 1 to 3 carbon atoms)-sulfonyl, R.sub.2 is morpholino, thiomorpholino, 1-oxido-thiomorpholino, 1,1-dioxido-thiomorpholino, piperazino or N'-[acetyl-(alkanoyl of 1 to 3 arbon atoms)]-piperazino, R.sub.3 is hydrogen, chlorine, bromine, nitro, cyano, formyl, acetyl or carbalkoxy of 2 to 4 carbon atoms, and R.sub.4 is hydrogen, chlorine, bromine, cyano, carbalkoxy of 2 to 4 carbon atoms, alkyl of 1 to 6 carbon atoms, mono(carbalkoxy of 2 to 4 carbon atoms)-alkyl of 1 to 6 carbon atoms, di(carbalkoxy of 2 to 4 carbon atoms)-alkyl of 1 to 6 carbon atoms, hydroxyl, allyloxy, alkoxy of 1 to 6 carbon atoms, mercapto, allylmercapto, (alkyl of 1 to 6 carbon atoms)-mercapto, 1-oxidothiomorpholino, or --NHB where B is hydrogen, alkyl of 1 to 3 carbon atoms, cyclohexyl, phenyl, chloro-phenyl, carboxy-phenyl, carbomethoxy-phenyl or pyridyl, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as the salts are useful as antithrombotics.

  化合物的公式为##SPC1##其中R.sub.1是1到3个碳原子的烷氧基，吗啡基，硫环氧基，1-氧代硫环氧基，1,1-二氧代硫环氧基或##EQU1##其中A是氢，1到4个碳原子的烷酰基，2到4个碳原子的烯酰基，甲氧基-(1到4个碳原子的烷酰基)，羧基-(1到4个碳原子的烷酰基)，乙酰基-(1到4个碳原子的烷酰基)，甲氧基-(2到4个碳原子的烯酰基)，羧基-(2到4个碳原子的烯酰基)，乙酰基-(2到4个碳原子的烯酰基)，氨基甲酰基，单(1到4个碳原子的烷基)-氨基甲酰基，双(1到4个碳原子的烷基)-氨基甲酰基，甲氧基甲基氨基甲酰基，吡啶酰基，水杨酰基，呋喃酰基或(1到3个碳原子的烷基)-磺酰基，R.sub.2是吗啡基，硫环氧基，1-氧代硫环氧基，1,1-二氧代硫环氧基，哌嗪基或N'-[乙酰-(1到3个碳原子的烷酰基)]-哌嗪基，R.sub.3是氢，氯，溴，硝基，氰基，甲酰基，乙酰基或2到4个碳原子的羧基烷氧基，R.sub.4是氢，氯，溴，氰基，2到4个碳原子的羧基烷氧基，1到6个碳原子的烷基，单(2到4个碳原子的羧基烷氧基)-1到6个碳原子的烷基，双(2到4个碳原子的羧基烷氧基)-1到6个碳原子的烷基，羟基，丙烯氧基，1到6个碳原子的烷氧基，硫醇基，丙烯硫醇基，(1到6个碳原子的烷基)-硫醇基，1-氧代硫环氧基或--NHB，其中B是氢，1到3个碳原子的烷基，环己基，苯基，氯苯基，羧基苯基，甲氧基苯基或吡啶基，以及其无毒、药理学上可接受的酸盐；这些化合物和盐作为抗血栓剂具有用处。
• Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K)
  申请人：Connolly Michael Kevin

  公开号：US20090227587A1

  公开（公告）日：2009-09-10

  The present invention provides pyrimidines of Formula I: wherein R 4 , R 6 , and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了式I的嘧啶类化合物：其中R4、R6和Y的值在说明书中有所定义，以及其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病、心血管疾病和癌症。还提供了包含一种或多种式I化合物的药物组合物。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Dransfield Paul John

  公开号：US20130079342A1

  公开（公告）日：2013-03-28

  Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  以下公式和含有它们的组合物，用于治疗一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病，如系统性红斑狼疮（SLE）、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化症、Sjogren综合症和自身免疫性溶血性贫血，包括所有过敏反应形式。本发明还能够治疗与p110活性相关、依赖或相关的癌症，包括但不限于白血病，如急性髓性白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增生性疾病（MPD）、慢性髓性白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体瘤，如乳腺癌。